GAS5 Gene Expression and IL-6 in Rheumatoid Arthritis
Expression of Growth Arrest-Specific 5 (GAS5) Long Non-Coding RNA and Serum Interlukin-6 Levels in Patients With Rheumatoid Arthritis
1 other identifier
observational
50
0 countries
N/A
Brief Summary
This study aims to investigate the expression of Growth Arrest-Specific 5 (GAS5) , a long non-coding RNA , in patients with Rheumatoid Arthritis compared with healthy individuals. The study will also assess the level of Interlukin-6 (IL-6) in the blood and explore the relationship between GAS5 expression and IL-6 levels in Rheumatoid Arthritis
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Oct 2026
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 27, 2026
CompletedFirst Posted
Study publicly available on registry
September 1, 2026
CompletedStudy Start
First participant enrolled
October 1, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
October 1, 2027
September 1, 2026
August 1, 2026
1 year
August 27, 2026
August 27, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
GAS5 gene expression level
GAS5 long non-coding RNA expression level in preipheral blood samples , assessed by quantitative real-time polymerase chain reaction (qRT-PCR) and compared between patients with rheumatoid arthritis and healthy controls
at enrollment
Study Arms (2)
Rheumatoid Arthritis
Participants diagnosed with Rhemutoid Arthritis who meet the predefined eligibility criteria and will undergo assessment of GAS5 gene expression and serum interlukin-6 (IL-6) levels
Healthy Controls
Healthy participants without Rheumatoid Arthritis who meet the predefined eligibilty criteria and will undergo assessment of GAS5 gene expression and serum interlukin-6 (IL-6)
Eligibility Criteria
Adult patients diagnosed with Rheumatoid Arthritis according to 2010 ACR/EULAR classification criteria and healthy controls participants who meet the predefined eligibility criteria
You may qualify if:
- Adult patients older than 18 years patients diagnosed with Rheumatoid Arthritis according to the 2010 American collage Rheumatology / European League against Rheumatism (ACR/EULAR) classification criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sohag Universitylead
Related Publications (1)
Hegazy GA-F, Shaker O, Aly O, Zaki HH, Herzalla MR, Gomaa AF, Sayed S, Haroon MM. Expression of Two Long Noncoding Ribonucleic Acids (Growth Arrest-Specific 5 and H19) in Rheumatoid Arthritis Patients: Relation to Clinical Characteristics and Disease Activity. Indian Journal of Rheumatology. 2021;16(2):152-158.
RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Samar Mohamed Abozaid, Biochemistry demonstrator
Faculty of Medicine , Sohag University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Demonstrator at Biochemistry and Molecular Biology department
Study Record Dates
First Submitted
August 27, 2026
First Posted
September 1, 2026
Study Start
October 1, 2026
Primary Completion (Estimated)
October 1, 2027
Study Completion (Estimated)
October 1, 2027
Last Updated
September 1, 2026
Record last verified: 2026-08